ACE-031
Also known as: ramatercept, ActRIIB-Fc
A soluble ActRIIB-Fc decoy receptor that sequesters myostatin and activin before they reach activin type II receptors, releasing the natural brake on skeletal muscle growth.
This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.
- Drug class
- Soluble ActRIIB-Fc fusion protein (myostatin/activin ligand trap)
- Primary targets
- Myostatin, Activin
- Dose reference
- Investigational only; trials used 0.02-3 mg/kg subcutaneously
- Half-life
- ~10-15 days
- Developer / origin
- Acceleron Pharma
- Reference year
- 2008
- Evidence score
- 3/5 - Moderate human evidence; discontinued for safety
Moderate human evidence; discontinued for safety
ACE-031 reached phase 1 and phase 2 human trials with clear muscle effects, but development was halted over vascular adverse events and it was never approved.
Limited human pharmacology or small clinical evidence.
Evidence basis
- Phase 1 showed significant increases in lean mass and thigh muscle volume
- Randomized phase 2 in Duchenne muscular dystrophy (stopped early)
- Halted after vascular adverse events (epistaxis, telangiectasias)
- No approved indication or validated human dose
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
ACE-031 guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Ipamorelin
NNC 26-0161
Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.
CJC-1295
DAC:GRF
Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.
Tesamorelin
Egrifta
Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
IGF-1 LR3
Long R3 IGF-1
A modified IGF-1 that binds IGF binding proteins far more weakly than native IGF-1, leaving it free to act as a potent, long-acting agonist at the IGF-1 receptor.
Category hub
Open the category page for the full comparison table and FAQ.